

Perfluoroalkyl Substances Exposure in Early Pregnancy and Preterm Birth in Singleton Pregnancies: A Prospective Cohort Study

Xiaona Huo

Shanghai Jiaotong University School of Medicine Xinhua Hospital

Lin Zhang

Shanghai Jiaotong University School of Medicine Xinhua Hospital

Rong Huang

Shanghai Jiaotong University School of Medicine Xinhua Hospital

Liping Feng

Shanghai Jiaotong University School of Medicine Xinhua Hospital

Weiye Wang

Shanghai Jiaotong University School of Medicine Xinhua Hospital

Jun Zhang (✉ junjimzhang@sina.com)

Shanghai Jiao Tong University School of Medicine <https://orcid.org/0000-0003-1706-1611>

Research

Keywords: birth cohort, perfluoroalkyl substances, pregnancy, duration of gestation, preterm birth

Posted Date: March 27th, 2020

DOI: <https://doi.org/10.21203/rs.2.17401/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Environmental Health on June 3rd, 2020.
See the published version at <https://doi.org/10.1186/s12940-020-00616-8>.

Abstract

Background: Preterm birth (PTB, < 37 completed weeks' gestation) is one of the global public health concerns. Epidemiologic evidence on the potential impact of perfluoroalkyl substances (PFAS) on PTB is still limited and inconsistent. We aimed to investigate the associations between prenatal PFAS exposure and PTB among singleton live births.

Methods: We studied 2849 mother-infant pairs in the Shanghai Birth Cohort (SBC) from 2013 to 2016. Ten PFAS in maternal plasma in early pregnancy (gestational age, median (interquartile range): 15 (13 - 16) weeks) were measured. Primary outcomes were duration of gestation, PTB, spontaneous PTB and clinically indicated PTB. A linear regression model was used to assess the associations between ln-transformed PFAS and duration of gestation (in weeks). Logistic regression models were applied to estimate the relative risks of these outcomes.

Results: The incidence of overall PTB was 4.8% (95% confidence limit: 4.0% - 5.6%, n = 136) in this study population. In the linear regression analyses, PFAS were not associated with the duration of gestation after controlling for potential confounders. In the multiple logistic models, no significant associations were observed between PFAS and overall PTB, spontaneous or indicated PTB.

Conclusion: Our prospective cohort study shows that maternal plasma PFAS concentrations in early pregnancy was not associated with gestational length, overall PTB, spontaneous or indicated PTB.

Background

Preterm birth (PTB), defined as a birth < 37 completed weeks' gestation, is one of the global public health problems with an average rate of 10.6% around the world [1, 2]. PTB is the leading cause of neonatal mortality and under-5 mortality worldwide in 2016 [1]. Children with PTB are at increased risks of long-term consequences such as impaired neurodevelopment, respiratory complications and gastrointestinal diseases [3]. Despite great efforts to reduce PTB [4, 5] in many countries, the incidence has not yet been significantly reduced. PTB is a particular concern in China as China has a minimum of 1 - 1.5 million preterm births each year and the incidence has been increasing in the past 2 - 3 decades [1, 5-7].

Environmental pollution, endocrine disrupting chemicals in particular, has been suspected to be one of the culprits [8]. For example, perfluoroalkyl substances (PFAS) are a subgroup of the widespread synthetic chemicals and persistent in the environment [9]. PFAS have excellent oil-repellent, water-repellent and dirt resistance characteristics [10]. They have been extensively used in household products (e.g., non-stick cookware, shampoo and carpets) since the 1950s [11]. Humans are exposed through oral ingestion, skin contact and inhalation [12].

Previous studies demonstrated that PFAS could change lipid metabolism [13], disrupt thyroid function [14], interfere glucose tolerance [13], and affect estrogen homeostasis [15]. It is, therefore, plausible that PFAS may cause PTB. However, epidemiologic evidence linking PFAS with PTB or length of gestation is

limited and inconsistent. Two birth cohort studies in Denmark and U.S. reported that the estimated risk for PTB in the higher quartiles of maternal perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS) exposure in early pregnancy was increased by 1.7 fold or more comparing to the lowest quartile [16, 17]. In addition, nearly 1.5-fold odds of PTB was found for per doubling increase of perfluoroheptane sulfonate (PFHpS) and perfluorodecanoic acid (PFDA) concentrations in the Danish study [17]. A 1.2-fold risk of PTB was reported for per interquartile range of perfluorononanoic acid (PFNA) in the U.S. study [16]. Chen et al. also found that a higher level of PFOS but not PFOA in the cord blood was associated with an increased risk of PTB (odds ratio: 2.5, 95% CI: 1.5, 4.1) [18]. In contrast, several other studies did not observe any significant associations [19-22].

The current study aimed to examine the associations between PFAS in early pregnancy and duration of gestation and risk of PTB in a large prospective cohort in Shanghai, China.

Methods

Study population

The study subjects in the current analysis were from the Shanghai Birth Cohort, a large prospective study in Shanghai, China, from 2013 to 2016 [23]. The inclusion criteria were couples aged 20 years or older, married, seeking preconception care or in early pregnancy, with spontaneous conception, at least one of them being registered residents in Shanghai with no plan to move out of Shanghai for two years after enrollment. The participants provided an informed consent before enrollment, and were interviewed by trained staffs to complete structured questionnaires on demographic characteristics, previous reproductive and medical history and lifestyle factors. They also provided blood samples voluntarily at the recruitment visit. Clinically relevant characteristics of the current pregnancy such as pregnancy complications, chronic diseases during current pregnancy, number of fetus, infant sex and gestational age at birth were extracted from medical records. An ethical approval was obtained from the Ethical Committee of the Xinhua Hospital affiliated to the Shanghai Jiao Tong University School of Medicine.

For the current analysis, a total of 3242 women who provided blood samples in early pregnancy (gestational age, median (interquartile range; IQR): 15 (13 - 16) weeks) and delivered a singleton live birth were eligible. Births with missing information on gestational age at birth, gestational age < 20 weeks or > 42 weeks were excluded (n = 289). Mothers or infants with missing information on maternal age at enrollment, pre-pregnancy body mass index (BMI), parental educational level, parity, chronic diseases during pregnancy or infant sex were excluded (n = 104). Finally, 2849 mother-infant pairs were included for analysis.

PFAS measurement

Blood samples were taken during early pregnancy and immediately centrifuged and frozen at -80 °C. A detailed analytical method has been described elsewhere [24]. In brief, PFAS concentrations were measured in 100 µl plasma using high-performance liquid chromatography/tandem mass spectrometry

(HPLC/MS-MS; Agilent1290–6490, Agilent Technologies Inc., USA). The intra- and inter-assay coefficients of variation were both below 10%. The limit of detection (LOD) was 0.09 ng/mL for PFOS and PFOA, 0.05 ng/mL for perfluorododecanoic acid (PFDoA), 0.03 ng/mL for perfluoroheptanoic acid (PFHpA), 0.02 ng/mL for PFDA, PFNA, perfluoroundecanoic acid (PFUA) and perfluorohexanesulfonate (PFHxS), 0.12 ng/mL for perfluorooctane sulfonamide (PFOSA), and 0.009 ng/mL for PFBS.

Outcome

The main outcome of this study was PTB, which was defined as birth between 21 and 36 completed weeks' gestation. Spontaneous PTB referred to spontaneous onset labor and preterm premature rupture of the membranes (PPROM) irrespective of mode of delivery (vaginal or cesarean section), while clinically indicated PTB was defined as PTB for preeclampsia, fetal stress, placenta previa and other maternal, fetal or placenta indications[3].

Covariates

Demographic characteristics included maternal age (< 30, 30 - 34, \geq 35 years old), parental education levels (\leq 12, > 12 years), smoking during pregnancy (no, yes, unknown), gestational age at blood collection. Obstetric and medical covariates included pre-pregnancy BMI (< 18.5, 18.5 - 24.9, \geq 25 kg/m²), parity (0, \geq 1), pregnancy complicated by chronic diseases (no, yes), and infant sex (female, male). Chronic diseases included heart, kidney or liver disease, diabetes mellitus, chronic hypertension disorders, epilepsy, malnutrition and anemia.

Analysis

Distributions of demographic and pregnancy related characteristics were showed as numbers and percentages. PFAS with concentrations below the LOD were assigned LOD/ . The distribution of PFAS in early pregnancy was presented as medians and interquartile ranges. Multivariable restricted cubic spline model was used to examine potential non-linear relationships between PFAS and gestational age (in weeks) at birth, according to the ln-transformed PFAS at three knots of 10th, 50th, 90th percentile. Univariable and multivariable linear regression analyses were used to evaluate the associations of ln-transformed PFAS with gestational age (in weeks) at birth. Simple and multiple logistic regression analyses were applied to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of the overall PTB, spontaneous PTB and clinically indicated PTB. In the logistic regression models, PFAS were entered as continuous variables (ln-transformed) and in tertile (untransformed) with the lowest tertile served as the reference group. Based on the directed acyclic graphs and existing literature, covariates were included in all adjusted models, including maternal age (years), pre-pregnancy BMI (kg/m²), parental education levels (\leq 12, > 12 years), parity (0, \geq 1), chronic diseases (no, yes), infant sex (female, male) and gestational week at blood collection. Because only few mothers (n = 9, 0.3%) smoked during early pregnancy, maternal smoking status was not included in the adjusted models.

To investigate the potential modification of infant sex, we performed a stratified analysis. To examine whether the associations differed among women who were multiparous, had preterm labor history, or complicated by chronic diseases, we carried out several subgroup analyses, restricting to women without these conditions, respectively.

Spearman's rank correlation coefficient was used to estimate the correlations between each pair of PFAS. As multicollinearity between PFAS may bias the estimated effects, we conducted linear regression or logistic regression models with mutual adjustment of the correlated PFAS ($\rho > 0.4$).

All analyses were carried out using SAS version 9.4 (IBM SAS Institute Inc, Cary, NC) and R software (R version 3.6.1). Results at $p < 0.05$ were thought to be statistically significant.

Results

Of all the 2849 women included in the present study, 136 (4.8%) gave a singleton live birth before 37 weeks' gestation, including 97 (71.3%) spontaneous PTB and 39 (28.7%) indicated PTB. More than 60% of the women aged less than 30 years and most of them were nulliparous (85.5%), nonsmokers (99.4%) and had normal weight ($18.5 < \text{BMI} < 25 \text{ kg/m}^2$) before pregnancy (74.4%). The vast majority (95.0 %) of couples had more than 12 years of education and only 197 (6.9%) women complicated with chronic diseases during pregnancy. In addition, the rate of boys and girls was 51.1% and 48.9%, respectively (Table 1).

PFOA, PFOS, PFNA, PFDA, PFUA and PFHxS were detected in all samples, whereas PFHpA, PFBS, PFD_oA and PFOSA were quantified in 82.6%, 81.2%, 83.1% and 19.6% of samples, respectively. PFOSA was not included in following analyses for a low detection rate ($< 80\%$). Median concentrations were 11.85, 9.33, 1.69, 1.69, 1.39, 0.54, 0.16, 0.06 and 0.04 ng/mL for PFOA, PFOS, PFNA, PFDA, PFUA, PFHxS, PFD_oA, PFHpA and PFBS, respectively (Table 2). Most PFAS generally showed high correlation between each other (Table S1).

Non-linearity was not detected for the association between any ln-transformed PFAS and gestational age at birth (in weeks) in a spline model (see Figure S1). No significant associations between ln-transformed PFAS and gestational age at birth (in weeks) were observed in linear regression after adjusting for potential confounders (Table 3). In the multiple logistic regression analyses, the estimated associations between PFAS and overall PTB, spontaneous PTB, and indicated PTB were non-significant when PFAS treated as continuous ln-transformed variables (Table 4). After categorizing PFAS into tertile variables, PFOS significantly decreased the risks of overall PTB (adjusted OR (aOR): 0.61, 95% CI: 0.40, 0.94) and spontaneous PTB (aOR: 0.56, 95% CI: 0.34, 0.94) comparing the middle tertile with the lowest tertile (see Table S2). However, the statistical significance disappeared after adjusting for correlated PFAS (data were not shown).

In the stratified analysis, the associations between continuous ln-transformed PFAS and overall PTB, spontaneous and indicated PTB did not differ by infant sex (see Table S3). In the subgroup analyses, the

main results remained unchanged when we restricted to women who were nulliparous or without chronic diseases (See Table S4 and S5).

Discussion

In this prospective study of 2849 mother-infant pairs, we observed no significant associations between maternal PFAS exposure in early pregnancy and the length of gestation, or the risks of overall PTB, spontaneous PTB or indicated PTB at the present exposure levels.

A previous cohort study of 3535 mother-infant pairs in Denmark found that the 3 upper quartiles of PFOA and PFOS in early pregnancy relative to the lowest quartile were significantly associated with PTB. This study also suggested an elevated risk of PTB for per doubling increase of PFHpS and PFDA concentrations [17]. However, this study was based on combined data and samples from three sub-studies. It was, therefore, less certain whether potential biases might have been introduced by the different study designs employed. Another relatively large birth cohort study (n = 1645) in Eastern Massachusetts reported that PFOS and PFNA exposures increased the risk of preterm birth [16], but the association was not significant for PFOA or PFHxS. The Taiwan Birth Panel Study included 429 mother-infant pairs to study four PFAS (PFOA, PFOS, PFNA, PFUA) and demonstrated that PFOS level was inversely associated with gestational age at birth (in weeks) and an increased risk of PTB [18]. However, PFAS were measured in cord blood in that study, rendering the causality uncertain.

In contrast to the above studies, we failed to find any association, which was supported by several other studies [19-22]. A Spanish birth cohort study (n = 1202) did not observe significant associations of maternal plasma PFOA, PFOS, PFHxS and PFNA in the first trimester with PTB [19]; a cohort study conducted in Canada (n = 252) reported that maternal serum PFOA, PFOS and PFHxS in the second trimester did not influence the risk of PTB [21]; the C8 Health Project in the United States measured the risk of PTB in a population with high PFOA exposure, still found no associations of PTB with PFOA or PFOS [22]. Two other studies estimated the prenatal PFOA exposure level through an assessment model and found no increased risk of preterm birth [25, 26]. Likewise, our study showed no associations between PFAS and length of gestation, which was also consistent with most previous studies [16, 17, 19, 21].

It should be mentioned that comparing results with previous studies was challenging because these studies were often incomparable in exposure level, study population and exposure window, all of which may affect the effect estimations. First, PFAS exposure levels among these studies varied widely. For instance, the PFOA level ranged from 1.3 ng/mL (geometric mean) [21] to 21.2 ng/mL (median) [20]. Second, exposure backgrounds differed tremendously across these studies as well. For example, the study population in the C8 Health Project lived in a highly PFOA exposed region. Third, divergences also existed in sample type (maternal vs. cord blood) and sampling time (before pregnancy, 1st trimester, 2nd trimester, in labor and after giving birth). It may not be ideal to compare the PFAS effects across studies with different exposure windows, since PFAS levels may vary between non-pregnancy, during pregnancy,

and after delivery. Forth, the sample size of these studies varied from 252 [21] to 5262 [20] participants and the PTB rate ranged between 3.2% [17] and 22.5% [20]. Finally, different study populations had different risk profiles. Compared with previous studies, participants in this study were more educated and nulliparous, and few reported smoking or alcohol drinking during pregnancy (see Table S6). Interpretation of our results, therefore, should take into account the background characteristics of our study population.

It is worth noting that none of the previous studies [16-22] differentiated clinical phenotypes of PTB. Since the underlying pathophysiology of PTB differs enormously between spontaneous and indicated PTB [3], it becomes essential to distinguish between these two types of PTB. The ability to assess PFAS exposure during early pregnancy in relation to the risk of subtypes of PTB is a notable strength of our study.

A recurrence risk of PTB could increase by 15% to 50% among women with a previous PTB [3]. On the contrary, birth as an elimination route may lead to lower PFAS blood concentrations [27]. Similarly, PFAS concentrations tend to decrease with higher parity [27], whereas the incidence of PTB appears to increase [28]. As a consequence, potential bias may arise from previous PTB or multiparity. To address this potential effect modification by parity, we repeated our analyses in nulliparous women. We were also able to examine the effects of PFAS in PTB by excluding women with chronic diseases. Our findings consistently suggested no association.

Several limitations of this study are worth noting. First, PTB was reported in one of our previous large-scale studies which conducted in 20 hospitals in Shanghai between 2015 and 2017 with an incidence rate of 5.6% [29]. The present study had a lower incidence of PTB (4.8%), which may be explained by the fact that our study did not include multiple gestation and pregnancies conceived with assisted reproductive technology, the subgroups carrying a substantial risk for PTB [3, 30]. Further, the method of gestational age estimation may influence the rate of PTB. Both the last menstrual period and early ultrasonic measurement were used [31]. Our study was conducted in Shanghai, one of the most advanced cities in China, where the content of prenatal care is comparable to those in western developed countries. Almost all pregnant women receive prenatal care and early ultrasound is performed routinely. The ultrasound measurement has been used to correct the calculated gestational age based on the last menstrual period. When the estimates of gestational age by these two methods differed by more than 2 weeks, the ultrasound estimate was used. Therefore, we believe that the gestational age estimate and PTB rate in our study were reasonably accurate.

Second, we did not adjust for hemodynamics in pregnancy in the analyses. Only two previous studies [16, 17] have adjusted for hemodynamic markers (plasma albumin and estimated glomerular filtration rate) in the assessment of associations between PFAS measured in early pregnancy and birth outcomes including PTB. But their results suggested that early pregnancy hemodynamics did not confound the associations. Instead, we adjusted for the gestational week at blood collection to control for the potential hemodynamic difference. The results were virtually the same. Therefore, our findings were less likely to be biased by early pregnancy hemodynamics. Third, while the evaluation of the associations of PFAS

exposure with spontaneous and indicated PTB separately was one strength of our study, the sample sizes of the subtypes of PTB were relatively small, which may have led to low precision in our effect estimates. Thus, it is worth noting that failure to detect a significant association does not necessarily mean that there is no effect. Fourth, although we have adjusted for a number of potential confounders, the possibility of residual confounding (e.g., gene, gene-environment interaction, household income) could not be ruled out. Our negative results should be interpreted with caution and need to be confirmed in large-scale studies in other populations.

Conclusions

Our study found no significant associations between maternal PFAS concentrations in early pregnancy and the length of gestation or the risk of PTB.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. All parents provided a written informed consent.

Consent for publication

Not applicable

Availability of data and materials

The dataset generated and/or analyzed in the current study are not publicly available but can be obtained from the corresponding author on a reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was partly funded by the National Natural Science Foundation of China (41991314; 81530086; 81803246), Shanghai Municipal Health Commission (GWIII-26, 20174Y0133, 201640032) and the Shanghai Jiao Tong University School of Medicine and supported by the National Human Genetic Resources Sharing Service Platform (2005DKA21300) and Xinhua Hospital Biobank.

Authors' contributions

JZ designed the original study. XH analyzed the data and drafted the manuscript. LZ and RH were major contributors in writing the manuscript. JZ, LF and WW substantially revised the manuscript. All authors

provided critical input to the paper. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Abbreviations

BMI, body mass index; CI, confidence interval; IQRs, interquartile ranges; LOD, limit of detection; OR, odds ratio; PTB, preterm birth; PPRM, preterm premature rupture of the membranes; PFAS, perfluoroalkyl substances; PFOA, perfluorooctanate; PFOS, perfluorooctane sulfonate; PFDA, perfluorodecanoic acid; PFUA, perfluoroundecanoic acid; PFNA, perfluorononanoic acid; PFHxS, perfluorohexanesulfonate; PFHpA, perfluoroheptanoic acid; PFBS, perfluorobutane sulfonate; PFDoA, perfluorododecanoic acid; PFOSA, perfluorooctane sulfonamide.

References

1. Chawanpaiboon S, Vogel JP, Moller AB, Lumbiganon P, Petzold M, Hogan D, Landoulsi S, Jampathong N, Kongwattanakul K, Laopaiboon M *et al*: **Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis.** *Lancet Glob Health* 2019, **7**(1):e37-e46.
2. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L *et al*: **National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications.** *Lancet* 2012, **379**(9832):2162-2172.
3. Goldenberg RL, Culhane JF, Iams JD, Romero R: **Epidemiology and causes of preterm birth.** *Lancet* 2008, **371**(9606):75-84.
4. Goldenberg RL, Rouse DJ: **Prevention of premature birth.** *N Engl J Med* 1998, **339**(5):313-320.
5. Zhao X, Chen Y, Qiu G, Xiao M, Zhong N: **Reducing preterm births in China.** *Lancet* 2012, **380**(9848):1144-1145; author reply 1145.
6. Zhong N: **Achieving Lower Preterm Birth Rates in China via Reductions in Iatrogenic Preterm Births.** *Am J Public Health* 2019, **109**(11):1489-1490.
7. Chen C, Zhang JW, Xia HW, Zhang HX, Betran AP, Zhang L, Hua XL, Feng LP, Chen D, Sun K *et al*: **Preterm Birth in China Between 2015 and 2016.** *Am J Public Health* 2019, **109**(11):1597-1604.
8. DiVall SA: **The influence of endocrine disruptors on growth and development of children.** *Curr Opin Endocrinol Diabetes Obes* 2013, **20**(1):50-55.
9. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J: **Perfluoroalkyl acids: a review of monitoring and toxicological findings.** *Toxicol Sci* 2007, **99**(2):366-394.
10. Lindstrom AB, Strynar MJ, Libelo EL: **Polyfluorinated compounds: past, present, and future.** *Environ Sci Technol* 2011, **45**(19):7954-7961.

11. Casals-Casas C, Desvergne B: **Endocrine disruptors: from endocrine to metabolic disruption.** *Annu Rev Physiol* 2011, **73**:135-162.
12. Fei C, McLaughlin JK, Tarone RE, Olsen J: **Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort.** *Environ Health Perspect* 2007, **115**(11):1677-1682.
13. Matilla-Santander N, Valvi D, Lopez-Espinosa MJ, Manzano-Salgado CB, Ballester F, Ibarluzea J, Santa-Marina L, Schettgen T, Guxens M, Sunyer J *et al.*: **Exposure to Perfluoroalkyl Substances and Metabolic Outcomes in Pregnant Women: Evidence from the Spanish INMA Birth Cohorts.** *Environ Health Perspect* 2017, **125**(11):117004.
14. Preston EV, Webster TF, Oken E, Claus Henn B, McClean MD, Rifas-Shiman SL, Pearce EN, Braverman LE, Calafat AM, Ye X *et al.*: **Maternal Plasma per- and Polyfluoroalkyl Substance Concentrations in Early Pregnancy and Maternal and Neonatal Thyroid Function in a Prospective Birth Cohort: Project Viva (USA).** *Environ Health Perspect* 2018, **126**(2):027013.
15. Wang H, Du H, Yang J, Jiang H, O K, Xu L, Liu S, Yi J, Qian X, Chen Y *et al.*: **PFOS, PFOA, estrogen homeostasis, and birth size in Chinese infants.** *Chemosphere* 2019, **221**:349-355.
16. Sagiv SK, Rifas-Shiman SL, Fleisch AF, Webster TF, Calafat AM, Ye X, Gillman MW, Oken E: **Early-Pregnancy Plasma Concentrations of Perfluoroalkyl Substances and Birth Outcomes in Project Viva: Confounded by Pregnancy Hemodynamics?** *Am J Epidemiol* 2018, **187**(4):793-802.
17. Meng Q, Inoue K, Ritz B, Olsen J, Liew Z: **Prenatal Exposure to Perfluoroalkyl Substances and Birth Outcomes; An Updated Analysis from the Danish National Birth Cohort.** *Int J Environ Res Public Health* 2018, **15**(9).
18. Chen MH, Ha EH, Wen TW, Su YN, Lien GW, Chen CY, Chen PC, Hsieh WS: **Perfluorinated compounds in umbilical cord blood and adverse birth outcomes.** *PLoS One* 2012, **7**(8):e42474.
19. Manzano-Salgado CB, Casas M, Lopez-Espinosa MJ, Ballester F, Iniguez C, Martinez D, Costa O, Santa-Marina L, Pereda-Pereda E, Schettgen T *et al.*: **Prenatal exposure to perfluoroalkyl substances and birth outcomes in a Spanish birth cohort.** *Environ Int* 2017, **108**:278-284.
20. Stein CR, Savitz DA, Dougan M: **Serum levels of perfluorooctanoic acid and perfluorooctane sulfonate and pregnancy outcome.** *Am J Epidemiol* 2009, **170**(7):837-846.
21. Hamm MP, Cherry NM, Chan E, Martin JW, Burstyn I: **Maternal exposure to perfluorinated acids and fetal growth.** *J Expo Sci Environ Epidemiol* 2010, **20**(7):589-597.
22. Darrow LA, Stein CR, Steenland K: **Serum perfluorooctanoic acid and perfluorooctane sulfonate concentrations in relation to birth outcomes in the Mid-Ohio Valley, 2005-2010.** *Environ Health Perspect* 2013, **121**(10):1207-1213.
23. Zhang J, Tian Y, Wang W, Ouyang F, Xu J, Yu X, Luo Z, Jiang F, Huang H, Shen X *et al.*: **Cohort profile: the Shanghai Birth Cohort.** *Int J Epidemiol* 2019, **48**(1):21-21g.
24. Zhou W, Zhang L, Tong C, Fang F, Zhao S, Tian Y, Tao Y, Zhang J, Shanghai Birth Cohort S: **Plasma Perfluoroalkyl and Polyfluoroalkyl Substances Concentration and Menstrual Cycle Characteristics in Preconception Women.** *Environ Health Perspect* 2017, **125**(6):067012.

25. Savitz DA, Stein CR, Bartell SM, Elston B, Gong J, Shin HM, Wellenius GA: **Perfluorooctanoic acid exposure and pregnancy outcome in a highly exposed community.** *Epidemiology* 2012, **23**(3):386-392.
26. Savitz DA, Stein CR, Elston B, Wellenius GA, Bartell SM, Shin HM, Vieira VM, Fletcher T: **Relationship of perfluorooctanoic acid exposure to pregnancy outcome based on birth records in the mid-Ohio Valley.** *Environ Health Perspect* 2012, **120**(8):1201-1207.
27. Park SK, Peng Q, Ding N, Mukherjee B, Harlow SD: **Determinants of per- and polyfluoroalkyl substances (PFAS) in midlife women: Evidence of racial/ethnic and geographic differences in PFAS exposure.** *Environ Res* 2019, **175**:186-199.
28. Babinszki A, Kerenyi T, Torok O, Grazi V, Lapinski RH, Berkowitz RL: **Perinatal outcome in grand and great-grand multiparity: effects of parity on obstetric risk factors.** *Am J Obstet Gynecol* 1999, **181**(3):669-674.
29. Zhang L, Zhang L, Li M, Xi J, Zhang X, Meng Z, Wang Y, Li H, Liu X, Ju F *et al*: **A cluster-randomized field trial to reduce cesarean section rates with a multifaceted intervention in Shanghai, China.** *BMC Med* 2020, **18**(1):27.
30. Jackson RA, Gibson KA, Wu YW, Croughan MS: **Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis.** *Obstet Gynecol* 2004, **103**(3):551-563.
31. Lynch CD, Zhang J: **The research implications of the selection of a gestational age estimation method.** *Paediatr Perinat Epidemiol* 2007, **21 Suppl 2**:86-96.

Tables

Table 1. Demographic and reproductive characteristics, n = 2,849.

Characteristic	n (%)
Maternal age (years)	
< 30	1811 (63.6)
30 - 34	845 (29.7)
≥ 35	193 (6.8)
Pre-pregnancy BMI* (kg/m²)	
< 18.5	435 (15.3)
18.5 - 24.9	2119 (74.4)
≥ 25	295 (10.4)
Parental educational level (years)	
≤ 12	142 (5.0)
> 12	2707 (95.0)
Smoking status in early pregnancy	
No	2831 (99.4)
Yes	9 (0.3)
Unknown	9 (0.3)
Parity	
0	2435 (85.5)
≥ 1	414 (14.5)
Pregnancy complicated by chronic diseases*	
No	2653 (93.1)
Yes	196 (6.9)
Infant sex	
Male	1456 (51.1)
Female	1393 (48.9)
Gestational age at blood drawn (weeks)	
Median (IQR)	15 (13 - 16)

*BMI: body mass index; Chronic diseases including heart disease, kidney or liver disease, diabetes mellitus, chronic hypertension disorders, epilepsy, malnutrition, anemia; IQR: interquartile range.

Table 2. The distribution of plasma concentration of PFAS (ng/mL) at the enrollment (n = 2,849).

PFAS	LOD	% < LOD	25 th percentile	Median	75 th percentile
PFOA	0.09	0	9.20	11.85	15.26
PFOS	0.09	0	6.54	9.33	13.65
PFDA	0.02	0	1.14	1.69	2.52
PFUA	0.02	0	0.94	1.39	2.05
PFNA	0.02	0	1.21	1.69	2.36
PFHxS	0.02	0	0.42	0.54	0.69
PFHpA	0.03	17.4	0.04	0.06	0.10
PFBS	0.009	18.8	0.02	0.04	0.06
PFDoA	0.05	16.9	0.10	0.16	0.25
PFOSA	0.12	80.4	--	--	--

Note: LOD: limit of detection; PFOA, perfluorooctanate; PFOS, perfluorooctane sulfonate; PFDA, perfluorodecanoic acid; PFUA, perfluoroundecanoic acid; PFNA, perfluorononanoic acid; PFHxS, perfluorohexanesulfonate; PFHpA, perfluoroheptanoic acid; PFBS, perfluorobutane sulfonate; PFDoA, perfluorododecanoic acid; PFOSA, perfluorooctane sulfonamide.

Table 3. Associations between PFAS concentrations in early pregnancy and gestational age (in weeks) at birth.

PFAS (ng/ml)	β (95% CI)	Adjusted* β (95% CI)
PFOA	0.00 (-0.13, 0.14)	-0.00 (-0.14, 0.13)
PFNA	0.03 (-0.07, 0.14)	0.03 (-0.08, 0.13)
PFDA	0.03 (-0.06, 0.12)	0.04 (-0.05, 0.13)
PFUA	0.07 (-0.02, 0.16)	0.06 (-0.03, 0.15)
PFOS	-0.02 (-0.12, 0.08)	0.02 (-0.08, 0.12)
PFHxS	-0.02 (-0.15, 0.10)	-0.02 (-0.14, 0.11)
PFHpA	0.02 (-0.04, 0.07)	0.02 (-0.05, 0.08)
PFBS	-0.01 (-0.09, 0.07)	0.02 (-0.05, 0.10)
PFDoA	0.10 (-0.01, 0.20)	0.08 (-0.02, 0.19)

Note: PFAS concentrations were measured in maternal plasma and have been ln-transformed before entering into the model.

* Adjusted for maternal age (years), pre-pregnancy BMI (kg/m^2), parity (0, ≥ 1), parental educational levels (≤ 12 , > 12 years), pregnancy complicating with chronic diseases (no, yes), infant sex (male, female) and gestational age at blood drawn (weeks).

Table 4. Associations between PFAS concentrations in early pregnancy and preterm birth.

PFAS (ng/ml)	Overall preterm birth		Spontaneous preterm birth		Indicated preterm birth	
	N _{preterm} =136/N _{term} =2713		N _{preterm} =97/N _{term} =2713		N _{preterm} =39/N _{term} =2713	
	OR (95% CI)	aOR* (95% CI)	OR (95% CI)	aOR* (95% CI)	OR (95% CI)	aOR* (95% CI)
PFOA	0.93 (0.62, 1.40)	0.92 (0.61, 1.33)	0.74 (0.45, 1.20)	0.73 (0.45, 1.19)	1.63 (0.78, 3.39)	1.71 (0.80, 3.67)
PFNA	0.85 (0.61, 1.18)	0.86 (0.61, 1.20)	0.81 (0.55, 1.19)	0.82 (0.56, 1.22)	0.94 (0.52, 1.71)	0.99 (0.53, 1.86)
PFDA	0.86 (0.65, 1.14)	0.88 (0.66, 1.17)	0.79 (0.57, 1.10)	0.80 (0.58, 1.12)	1.06 (0.64, 1.76)	1.14 (0.67, 1.93)
PFUA	0.79 (0.59, 1.05)	0.82 (0.61, 1.10)	0.77 (0.55, 1.07)	0.78 (0.56, 1.10)	0.83 (0.50, 1.41)	0.93 (0.54, 1.61)
PFOS	0.88 (0.64, 1.19)	0.86 (0.63, 1.17)	0.79 (0.55, 1.14)	0.77 (0.53, 1.11)	1.12 (0.65, 1.95)	1.13 (0.64, 2.01)
PFHxS	1.16 (0.80, 1.69)	1.16 (0.79, 1.71)	1.05 (0.67, 1.65)	1.03 (0.65, 1.63)	1.45 (0.76, 2.69)	1.58 (0.82, 3.05)
PFHpA	0.96 (0.80, 1.16)	0.95 (0.78, 1.15)	0.93 (0.74, 1.16)	0.91 (0.72, 1.14)	1.04 (0.74, 1.47)	1.06 (0.74, 1.53)
PFBS	1.09 (0.85, 1.39)	1.06 (0.83, 1.37)	0.94 (0.70, 1.26)	0.93 (0.69, 1.25)	1.49 (0.96, 2.32)	1.44 (0.91, 2.26)
PFDoA	0.71 (0.50, 1.01)	0.73 (0.51, 1.04)	0.82 (0.66, 1.01)	0.82 (0.66, 1.03)	0.73 (0.39, 1.35)	0.82 (0.53, 1.58)

Note: PFAS concentrations were measured in maternal plasma and have been ln-transformed before entering into the model.

* Adjusted for maternal age (years), pre-pregnancy BMI (kg/m²), parity (0, ≥1), parental educational levels (≤12, >12 years), pregnancy complicating with chronic diseases (no, yes), infant sex (male, female) and gestational age at blood drawn (weeks).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigureS3.tif](#)
- [FigureS1.tif](#)
- [FigureS2.tif](#)
- [SupplementaryTables.docx](#)